Press releases
- MindMed to Participate at May Investor Conferences
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
- MindMed Reports First Quarter 2024 Financial Results and Business Updates
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
- MindMed to Present at Upcoming May Medical Conferences
- MindMed to Present at Upcoming April Medical Conferences
- MindMed Announces Voluntary Delisting from Cboe Canada
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
More ▼
Key statistics
On Monday, Mind Medicine (MindMed) Inc (MMQ:FRA) closed at 7.65, -36.45% below its 52-week high of 12.03, set on Apr 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.65 |
---|---|
High | 7.65 |
Low | 7.65 |
Bid | 7.43 |
Offer | 7.65 |
Previous close | 7.68 |
Average volume | 359.43 |
---|---|
Shares outstanding | 71.87m |
Free float | 69.95m |
P/E (TTM) | -- |
Market cap | 590.79m USD |
EPS (TTM) | -2.94 USD |
Data delayed at least 15 minutes, as of May 20 2024 07:16 BST.
More ▼